Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Review Article

Ketogenic Diet Therapy for Glioma: Combined Effects

Author(s): Hongyu Qin, Fan Zhang and Shuqing Gao*

Volume 20, Issue 2, 2024

Published on: 21 September, 2023

Page: [177 - 187] Pages: 11

DOI: 10.2174/1573394719666230717160843

Price: $65

Abstract

The ketogenic diet (KD) has made a breakthrough in the treatment of glioma and has become a research hotspot because of its unique dietary structure, particularly as an auxiliary strategy for anti-tumor. This article reviews the application and mechanism of KD combined with other antitumor methods, such as chemoradiotherapy, immunotherapy, molecularly targeted drugs, antiangiogenic drugs, glucose-targeted drugs, hyperbaric oxygen, ketone bodies, and intestinal flora, aiming to provide a theoretical basis for the clinical application of KD.

Keywords: Ketogenic diets, cancer, glioma, diet therapy, rapamycin, combined application.

Graphical Abstract
[1]
Aaron CT, David MA, Giselle YL, Michael M, Henry SF, Mustafa K. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 2020; 70(4)
[2]
Ristow M. Oxidative metabolism in cancer growth. Curr Opin Clin Nutr Metab Care 2006; 9(4): 339-45.
[http://dx.doi.org/10.1097/01.mco.0000232892.43921.98] [PMID: 16778561]
[3]
Rodrigues LM, Uribe-Lewis S, Madhu B, Honess DJ, Stubbs M, Griffiths JR. The action of β-hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a β-hydroxybutyrate paradox. Cancer Metab 2017; 5(1): 4.
[http://dx.doi.org/10.1186/s40170-017-0166-z] [PMID: 28261475]
[4]
Hyde PN, Lustberg MB, Miller VJ, LaFountain RA, Volek JS. Pleiotropic effects of nutritional ketosis: Conceptual framework for keto-adaptation as a breast cancer therapy. Cancer Treat Res Commun 2017; 12: 32-9.
[http://dx.doi.org/10.1016/j.ctarc.2017.06.001]
[5]
Fine EJ, Segal-Isaacson CJ, Feinman RD, et al. A pilot safety and feasibility trial of a reduced carbohydrate diet in patients with advanced cancer. J Clin Oncol 2011; 29(15): e13573.
[6]
Jansen N, Walach H. The development of tumours under a ketogenic diet in association with the novel tumour marker TKTL1: A case series in general practice. Oncol Lett 2016; 11(1): 584-92.
[http://dx.doi.org/10.3892/ol.2015.3923] [PMID: 26870251]
[7]
Chang HT, Olson L, Schwartz KA. Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. Nutr Metab 2013; 10(1): 47.
[http://dx.doi.org/10.1186/1743-7075-10-47] [PMID: 23829383]
[8]
Woodhouse C, Ward T, Gaskill-Shipley M, Chaudhary R. Feasibility of a modified Atkins diet in glioma patients during radiation and its effect on radiation sensitization. Curr Oncol 2019; 26(4): 433-8.
[http://dx.doi.org/10.3747/co.26.4889] [PMID: 31548811]
[9]
Noorlag L, De Vos FY, Kok A, et al. Treatment of malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies. Clin Nutr 2019; 38(5): 1986-94.
[http://dx.doi.org/10.1016/j.clnu.2018.10.024] [PMID: 30473444]
[10]
Champ CE, Palmer JD, Volek JS, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol 2014; 117(1): 125-31.
[http://dx.doi.org/10.1007/s11060-014-1362-0] [PMID: 24442482]
[11]
Acharya P, Acharya C, Thongprayoon C, et al. Incidence and characteristics of kidney stones in patients on ketogenic diet: A systematic review and meta-analysis. Diseases 2021; 9(2): 39.
[http://dx.doi.org/10.3390/diseases9020039] [PMID: 34070285]
[12]
Branco AF, Ferreira A, Simões RF, et al. Ketogenic diets: From cancer to mitochondrial diseases and beyond. Eur J Clin Invest 2016; 46(3): 285-98.
[http://dx.doi.org/10.1111/eci.12591] [PMID: 26782788]
[13]
Locke EJ, Vinovrski MF, Walborn L, et al. The ketogenic diet impairs mitochondrial function in hearts of male and female mice. FASEB J 2022; 36(S1)
[http://dx.doi.org/10.1096/fasebj.2022.36.S1.R5954]
[14]
Liao YJ, Wang YH, Wu CY, Hsu FY, Chien CY, Lee YC. Ketogenic diet enhances the cholesterol accumulation in liver and augments the severity of CCl4 and TAA-induced liver fibrosis in mice. Int J Mol Sci 2021; 22(6): 2934.
[http://dx.doi.org/10.3390/ijms22062934] [PMID: 33805788]
[15]
Liśkiewicz AD, Kasprowska D, Wojakowska A, et al. Long-term high fat ketogenic diet promotes renal tumor growth in a rat model of tuberous sclerosis. Sci Rep 2016; 6(1): 21807.
[http://dx.doi.org/10.1038/srep21807] [PMID: 26892894]
[16]
Chen GL, Luo Y, Eriksson D, et al. High fat diet increases melanoma cell growth in the bone marrow by inducing osteopontin and inter-leukin 6. Oncotarget 2016; 7(18): 26653-69.
[http://dx.doi.org/10.18632/oncotarget.8474] [PMID: 27049717]
[17]
Nebeling LC, Lerner E. Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc 1995; 95(6): 693-7.
[http://dx.doi.org/10.1016/S0002-8223(95)00189-1] [PMID: 7759747]
[18]
Nebeling LC, Miraldi F, Shurin SB, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: Two case reports. J Am Coll Nutr 1995; 14(2): 202-8.
[http://dx.doi.org/10.1080/07315724.1995.10718495] [PMID: 7790697]
[19]
Zeng Q, Stylianou T, Preston J, et al. The ketogenic diet alters the epigenetic landscape of GBM to potentiate the effects of chemotherapy and radiotherapy. Neuro-oncol 2019; 21(S4): iv8.
[http://dx.doi.org/10.1093/neuonc/noz167.033]
[20]
Santos JG, Da Cruz WMS, Schönthal AH, et al. Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma. Oncol Lett 2018; 15(1): 1263-70.
[PMID: 29391903]
[21]
Stapinska-Syniec A, Grabiec M, Rylski M, Acewicz A, Sobstyl M. DNA hydroxymethylation in high-grade gliomas. J Neurol Surg A Cent Eur Neurosurg 2021; 83(6): 568-72.
[PMID: 34872125]
[22]
Ram AK, Vairappan B. Role of zonula occludens in gastrointestinal and liver cancers. World J Clin Cases 2022; 10(12): 3647-61.
[http://dx.doi.org/10.12998/wjcc.v10.i12.3647] [PMID: 35647143]
[23]
Patabendige A, Chen R. Astrocytic aquaporin 4 subcellular translocation as a therapeutic target for cytotoxic edema in ischemic stroke. Neural Regen Res 2022; 17(12): 2666-8.
[http://dx.doi.org/10.4103/1673-5374.339481] [PMID: 35662202]
[24]
Abdelwahab MG, Fenton KE, Preul MC, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malig-nant glioma. PLoS One 2012; 7(5): e36197.
[http://dx.doi.org/10.1371/journal.pone.0036197] [PMID: 22563484]
[25]
Augur ZM, Doyle CM, Li M, Mukherjee P, Seyfried TN. Nontoxic targeting of energy metabolism in preclinical vm-m3 experimental glio-blastoma. Front Nutr 2018; 5: 91.
[http://dx.doi.org/10.3389/fnut.2018.00091] [PMID: 30349820]
[26]
Elsakka AMA, Bary MA, Abdelzaher E, et al. Management of glioblastoma multiforme in a patient treated with ketogenic metabolic therapy and modified standard of care: A 24-month follow-up. Front Nutr 2018; 5: 20.
[http://dx.doi.org/10.3389/fnut.2018.00020] [PMID: 29651419]
[27]
Zuccoli G, Marcello N, Pisanello A, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet. Case Report Nutr Metab 2010; 7(1): 33.
[http://dx.doi.org/10.1186/1743-7075-7-33] [PMID: 20412570]
[28]
Sun W, Yang J, Liu B, et al. Ketogenic diet inhibits tumor growth by enhancing immune response, attenuating immunosuppression, inhibiting angiogenesis and EMT in CT26 colon tumor allografts mouse model. J Funct Foods 2022; 92: 105067.
[http://dx.doi.org/10.1016/j.jff.2022.105067]
[29]
Fouad NM, Abdou EYG, Tarif HM, Nasser MM, Nesrine R. Effect of ketogenic diet for drug-resistant epilepsy on immunological cells. Neurol Sci 2021; 43(3): 1987-92.
[30]
Simon H, Gabriele S, David E, Xaver M, Alicia F. Very-low-carbohydrate diet enhances human T-cell immunity through immunometabolic reprogramming. EMBO Mol Med 2021; 13(8)
[31]
Xiaoming D, Xia B, Yang G, et al. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint block-ade. Mol Cell 2021; 81(11)
[32]
Wang Z, Han Q, Wang J, Yao W, Wang L, Li K. Rapamycin induces autophagy and apoptosis in Kaposiform hemangioendothelioma primary cells in vitro. J Pediatr Surg 2022; 57(7): 1274-80.
[http://dx.doi.org/10.1016/j.jpedsurg.2022.02.032] [PMID: 35428493]
[33]
Shimano KA, Eng W, Adams DM. How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies. Pediatr Blood Cancer 2022; 69(S3): e29603.
[34]
Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8(2): 128-35.
[http://dx.doi.org/10.1038/nm0202-128] [PMID: 11821896]
[35]
Zou Y, Fineberg S, Pearlman A, Feinman RD, Fine EJ. The effect of a ketogenic diet and synergy with rapamycin in a mouse model of breast cancer. PLoS One 2020; 15(12): e0233662.
[http://dx.doi.org/10.1371/journal.pone.0233662] [PMID: 33270630]
[36]
Shah S, Rodriguez G, Musick A, et al. Targeting glioblastoma stem cells with 2-deoxy-d-glucose (2-DG) potentiates radiation-induced unfolded protein response (UPR). Cancers 2019; 11(2): 159.
[http://dx.doi.org/10.3390/cancers11020159] [PMID: 30709011]
[37]
Shukla A, Gupta P, Singh R, Mishra DP. Glycolytic inhibitor 2-Deoxy-d-Glucose activates migration and invasion in glioblastoma cells through modulation of the miR-7-5p/TFF3 signaling pathway. Biochem Biophys Res Commun 2018; 499(4): 829-35.
[http://dx.doi.org/10.1016/j.bbrc.2018.04.001] [PMID: 29621542]
[38]
Huang Y, Sun G, Sun X, et al. The potential of lonidamine in combination with chemotherapy and physical therapy in cancer treatment. Cancers 2020; 12(11): 3332.
[http://dx.doi.org/10.3390/cancers12113332] [PMID: 33187214]
[39]
Kumar V, Singh P, Gupta SK, Ali V. Jyotirmayee, Verma M. Alterations in cellular metabolisms after Imatinib therapy: A review. Med Oncol 2022; 39(7): 95.
[http://dx.doi.org/10.1007/s12032-022-01699-8] [PMID: 35570245]
[40]
Dadgostar E, Fallah M, Izadfar F, et al. Therapeutic potential of resveratrol in the treatment of glioma: Insights into its regulatory mechanisms. Mini Rev Med Chem 2021; 21(18): 2835-47.
[http://dx.doi.org/10.2174/1389557521666210406164758] [PMID: 33823776]
[41]
Marsh J, Mukherjee P, Seyfried TN. Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutr Metab 2008; 5(1): 33.
[http://dx.doi.org/10.1186/1743-7075-5-33] [PMID: 19032781]
[42]
Liu Y, Zhang Y, Mao X, et al. Palliative treatment efficacy of glucose inhibition combined with chemotherapy for non small cell lung cancer with widespread bone and brain metastases: A case report. Biomed Rep 2017; 7(6): 553-7.
[http://dx.doi.org/10.3892/br.2017.1008] [PMID: 29250326]
[43]
Oleksyszyn J. The complete control of glucose level utilizing the composition of ketogenic diet with the gluconeogenesis inhibitor, the anti-diabetic drug metformin, as a potential anti-cancer therapy. Med Hypotheses 2011; 77(2): 171-3.
[http://dx.doi.org/10.1016/j.mehy.2011.04.001] [PMID: 21530093]
[44]
Zou X, Tang XY, Qu ZY, et al. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review. Int J Biol Macromol 2022; 202: 539-57.
[http://dx.doi.org/10.1016/j.ijbiomac.2022.01.113] [PMID: 35074329]
[45]
Larysz D, Kula D, Kowal M, et al. Epidermal growth factor receptor gene expression in high grade gliomas. Folia Neuropathol 2011; 49(1): 28-38.
[PMID: 21455841]
[46]
Koochekpour S, Bullock P, Dean AF, Pilkington GJ, Merzak A. Expression of vascular endothelial growth-factor in the cyst fluid of human cerebral gliomas. Oncol Rep 1995; 2(6): 1147-9.
[http://dx.doi.org/10.3892/or.2.6.1147] [PMID: 21597873]
[47]
Al-Anazi M, Khairuddean M, Al-Najjar BO, Alidmat MM, Kamal N, Muhamad M. Synthesis, anticancer activity and docking studies of pyrazoline and pyrimidine derivatives as potential epidermal growth factor receptor (EGFR) inhibitors. Arab J Chem 2022; 15(7): 10.
[http://dx.doi.org/10.1016/j.arabjc.2022.103864]
[48]
Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management. Nat Rev Clin Oncol 2022; 19(8): 499-514.
[http://dx.doi.org/10.1038/s41571-022-00639-9]
[49]
Kumar NM, Nukala SK, Thirukovela NS, et al. Ramachary-bressy-Wang 3+2 cycloaddition reaction: Synthesis of fully decorated 1,2,3-triazoles as potent anticancer and EGFR inhibitors. J Mol Struct 2022; 1262: 11.
[50]
Wang C, Jiang M, Hou H, Lin Q, Yan Z, Zhang X. Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma. Oncol Lett 2018; 16(5): 5607-14.
[http://dx.doi.org/10.3892/ol.2018.9355] [PMID: 30344715]
[51]
Yao H, Liu J, Zhang C, et al. Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas. J Clin Neurosci 2021; 90: 82-8.
[http://dx.doi.org/10.1016/j.jocn.2021.05.032] [PMID: 34275586]
[52]
de Marcellus C, Tauziède-Espariat A, Cuinet A, et al. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients. J Neurooncol 2022; 157(2): 355-64.
[http://dx.doi.org/10.1007/s11060-022-03970-4] [PMID: 35239111]
[53]
Ruiz J, Case D, Enevold G, et al. A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. J Neurooncol 2012; 106(3): 611-7.
[http://dx.doi.org/10.1007/s11060-011-0698-y] [PMID: 21870118]
[54]
Hassler MR, Sax C, Flechl B, et al. Thalidomide as palliative treatment in patients with advanced secondary glioblastoma. Oncology 2015; 88(3): 173-9.
[http://dx.doi.org/10.1159/000368903] [PMID: 25427949]
[55]
Feng S, Wang H, Wang Y, et al. Apatinib induces 3‐hydroxybutyric acid production in the liver of mice by peroxisome proliferator‐activated receptor α activation to aid its antitumor effect. Cancer Sci 2019; 110(10): 3328-39.
[http://dx.doi.org/10.1111/cas.14168] [PMID: 31429167]
[56]
Stavtizski NM, Landon CS, Hinojo CM, et al. Ketone ester supplementation does not impair cognitive or motor performance and delays CNS oxygen toxicity in male sprague‐dawley rats. FASEB J 2020; 34(S1): 1.
[http://dx.doi.org/10.1096/fasebj.2020.34.s1.04339]
[57]
Soliven MA, Williams MS, Rogers CQ, D’Agostino DP. Oral administration of a novel, synthetic ketogenic compound elevates blood beta-hydroxybutyrate levels in mice in both food-restricted and ab-libitum conditions. FASEB J 2022; 36(S1)
[58]
Chriett S, Dąbek A, Wojtala M, Vidal H, Balcerczyk A, Pirola L. Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule. Sci Rep 2019; 9(1): 742.
[http://dx.doi.org/10.1038/s41598-018-36941-9] [PMID: 30679586]
[59]
Wang Q, Zhou Y, Rychahou P, et al. Ketogenesis contributes to intestinal cell differentiation. Cell Death Differ 2017; 24(3): 458-68.
[http://dx.doi.org/10.1038/cdd.2016.142] [PMID: 27935584]
[60]
Dmitrieva-Posocco O, Wong AC, Lundgren P, et al. β-Hydroxybutyrate suppresses colorectal cancer. Nature 2022; 605(7908): 160-5.
[http://dx.doi.org/10.1038/s41586-022-04649-6] [PMID: 35477756]
[61]
Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Metabolic management of brain cancer. Biochim Biophys Acta 2010; 1807(6): 577-94.
[62]
Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007; 117(8): 2197-204.
[http://dx.doi.org/10.1172/JCI32205] [PMID: 17657310]
[63]
Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342(6161): 971-6.
[http://dx.doi.org/10.1126/science.1240537] [PMID: 24264990]
[64]
Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342(6161): 967-70.
[http://dx.doi.org/10.1126/science.1240527] [PMID: 24264989]
[65]
Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 2015; 350(6264): 1084-9.
[http://dx.doi.org/10.1126/science.aac4255] [PMID: 26541606]
[66]
Attaye I, van Oppenraaij S, Warmbrunn MV, Nieuwdorp M. The role of the gut microbiota on the beneficial effects of ketogenic diets. Nutrients 2021; 14(1): 191.
[http://dx.doi.org/10.3390/nu14010191] [PMID: 35011071]
[67]
Olson CA, Iñiguez AJ, Yang GE, et al. Alterations in the gut microbiota contribute to cognitive impairment induced by the ketogenic diet and hypoxia. Cell Host Microbe 2021; 29(9): 1378-1392.e6.
[http://dx.doi.org/10.1016/j.chom.2021.07.004] [PMID: 34358434]
[68]
Iyikesici MS. Survival outcomes of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy in advanced gastric cancer. Niger J Clin Pract 2020; 23(5): 734-40.
[PMID: 32367884]
[69]
Iyikesici MS. Preliminary results of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in stage II-IV rectal cancer. Arch Clin Exp Med 2020; 5(1): 16-20.
[70]
Iyikesici MS. Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer. Int J Hyperthermia 2019; 36(1): 445-54.
[http://dx.doi.org/10.1080/02656736.2019.1589584] [PMID: 30931666]
[71]
Poff AM, Ward N, Seyfried TN, Arnold P, D’Agostino DP. Non-toxic metabolic management of metastatic cancer in VM mice: Novel combination of ketogenic diet, ketone supplementation, and hyperbaric oxygen therapy. PLoS One 2015; 10(6): e0127407.
[http://dx.doi.org/10.1371/journal.pone.0127407] [PMID: 26061868]

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy